The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The OUTBACK Trial - The Role Of Adjuvant Chemotherapy In Locally Advanced Cervical Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,472,782.00
Summary
This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group ....This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.Read moreRead less
Improving Risk Evaluation And Outcomes In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$798,022.00
Summary
The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and high risk genetic changes in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.
An International Clinical Trial To Evaluate New Therapies To Improve Survival Of Children With Relapsed Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$1,567,500.00
Summary
Children who relapse with childhood leukaemia have only a 50% chance of being alive after 5 years. We will participate in a new international trial involving most European and all Australian and New Zealand childhood oncology centres, to test the effectiveness of promising new treatments and to perform biological studies which should enable doctors in future to pick the best treatment for each of these patients.